The first pilot study of ICI in dogs was performed in Japan, where the in vitro immunomodulatory effects of c4G12, a canine-chimerised anti-PD-L1 monoclonal antibody, and the clinical efficacy in dogs with various cancers were evaluated [5]. This evidence concerns the gene CD274 and cancer.